Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib
CONCLUSION: The experimental evidence presented highlights the fact that proton pump inhibitors have potential to inhibit P-glycoprotein, giving rise to drug interactions with palbociclib and ribociclib. Hence, monitoring is required while proton pump inhibitors and cyclin-dependent kinase inhibitors are being co-administered to avoid adverse events.PMID:37581514 | DOI:10.2174/1389200224666230815122312 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - August 15, 2023 Category: Drugs & Pharmacology Authors: Mrunal Pradeep Desai Prajakta Harish Patil Sai Krishna Anand Vullendula Sumit Birangal G Gautham Shenoy Mahadev Rao Swapnil Jayant Dengale Krishnamurthy Bhat Jagadish Puralae Channabasavaiah Source Type: research
Voriconazole-induced visual abnormality based on drug interaction between voriconazole and esomeprazole: A case report
We report a case of voriconazole-induced visual abnormality based on drug interaction of voriconazole and esomeprazole, therapeutic drug monitoring, and optimal therapy. An 81-year-old male developed visual abnormality after the blood concentration of voriconazole was up to 6.47 mg/L induced by coadministration with esomeprazole. Voriconazole is a substrate of multiple CYP450 isoenzymes including CYP2C19 (the major route), CYP3A4, and CYP2C9. Esomeprazole, a proton pump inhibitor (PPI), is also converted to inactive metabolites through CYP3A4 and CYP2C19-mediated metabolism, and is also a CYP2C19 inhibitor. The coadministr...
Source: Clinical Pharmacology and Therapeutics - August 7, 2023 Category: Drugs & Pharmacology Authors: Zhouqian Jiang Jia Li Chengfei Zhao Jie Chen Source Type: research
Voriconazole-induced visual abnormality based on drug interaction between voriconazole and esomeprazole: A case report
We report a case of voriconazole-induced visual abnormality based on drug interaction of voriconazole and esomeprazole, therapeutic drug monitoring, and optimal therapy. An 81-year-old male developed visual abnormality after the blood concentration of voriconazole was up to 6.47 mg/L induced by coadministration with esomeprazole. Voriconazole is a substrate of multiple CYP450 isoenzymes including CYP2C19 (the major route), CYP3A4, and CYP2C9. Esomeprazole, a proton pump inhibitor (PPI), is also converted to inactive metabolites through CYP3A4 and CYP2C19-mediated metabolism, and is also a CYP2C19 inhibitor. The coadministr...
Source: International Journal of Clinical Pharmacology and Therapeutics - August 7, 2023 Category: Drugs & Pharmacology Authors: Zhouqian Jiang Jia Li Chengfei Zhao Jie Chen Source Type: research
December 2018 (vol. 219, no. 4, pages 388.e1-17)
Cluver CA, Hannan NJ, van Papendorp E, et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. Am J Obstet Gynecol 2018;219:388.e1-17. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - August 4, 2023 Category: OBGYN Tags: Correction Source Type: research
A day-to-day management model improves patient compliance to treatment for Helicobacter pylori infection: a prospective, randomized controlled study
ConclusionThis study demonstrated the novel application of the DTD model in the treatment ofH. pylori infection, which enabled patients to develop habitual medication-taking behaviors without physician intervention. (Source: Gut Pathogens)
Source: Gut Pathogens - July 31, 2023 Category: Microbiology Source Type: research
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases
CONCLUSION: This study has confirmed using big data, that EPZ, the optical isomer and racemic form of omeprazole, has the beneficial characteristics of being less sensitive to CYP, as was intended by its design.PMID:37482254 | DOI:10.1016/j.taap.2023.116632 (Source: Toxicology and Applied Pharmacology)
Source: Toxicology and Applied Pharmacology - July 23, 2023 Category: Toxicology Authors: Mami Neishi Hirofumi Hamano Takahiro Niimura Masaya Denda Kenta Yagi Koji Miyata Tsung-Jen Lin Tsukasa Higashionna Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Hideki Nawa Source Type: research
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases
CONCLUSION: This study has confirmed using big data, that EPZ, the optical isomer and racemic form of omeprazole, has the beneficial characteristics of being less sensitive to CYP, as was intended by its design.PMID:37482254 | DOI:10.1016/j.taap.2023.116632 (Source: Toxicology and Applied Pharmacology)
Source: Toxicology and Applied Pharmacology - July 23, 2023 Category: Toxicology Authors: Mami Neishi Hirofumi Hamano Takahiro Niimura Masaya Denda Kenta Yagi Koji Miyata Tsung-Jen Lin Tsukasa Higashionna Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Hideki Nawa Source Type: research
Pharmacokinetics, Safety, and Tolerability of Vonoprazan ‐ or Esomeprazole‐Based Bismuth‐Containing Quadruple Therapy: A Phase 1, Double‐Blind, Parallel‐Group Study in Adults with Helicobacter pylori Infection in China
In conclusion, vonoprazan had no significant effect on plasma bismuth exposure compared with esomeprazole. (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - July 14, 2023 Category: Drugs & Pharmacology Authors: Jia Miao,
Chao Hu,
Jie Tang,
Wenyan Wang,
Ying Wang,
Ruoting Men,
Li Yang,
Liqun Gu,
Naoki Yoshida,
Richard Czerniak Tags: Original Article Source Type: research
Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric ‐Coated Capsules in Healthy Chinese Subjects
AbstractThis bioequivalence study is critically important for drug production. Recently, a local pharmaceutical company produced esomeprazole magnesium enteric-coated capsules, a major drug to help to eradicateHelicobacter pylori, but the bioequivalence is not well known. The present study aimed to evaluate the bioequivalence of the 2 esomeprazole magnesium enteric-coated capsules and their pharmacokinetics and safety in 3 biological equivalence trials: fasting, feeding, and mixing. The fasting and mixing trials used single-centered randomized, open-label, single-dose, 2-treatment, 2-period, and 2-sequence crossover design...
Source: Clinical Pharmacology in Drug Development - July 1, 2023 Category: Drugs & Pharmacology Authors: Juan Jin,
Cuiping Huang,
Changhai Zhu,
Wanni Feng,
Ang He,
Tuo Li,
Lina Wang,
Xiaolu Wang,
Xiali Rao,
Fangliang Gan Tags: Original Article Source Type: research
Comparison of the acid suppression effects between low-dose esomeprazole and famotidine in healthy subjects
CONCLUSION: The PD parameters of esomeprazole 10 mg were comparable to those of famotidine after multiple doses. These findings provide support for further evaluating the use of 10 mg of esomeprazole as a treatment option for gastritis.PMID:37382329 | DOI:10.5414/CP204391 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - June 29, 2023 Category: Drugs & Pharmacology Authors: Ha-Yeon Kim Jun Gi Hwang Jae-Won Kim Chang Hwan Seong Ji Hyeon Lee Hyung Son Kim Hye Yun Kim Yu Kyong Kim Min Kyu Park Source Type: research
